References
<A NAME="RS05503ST-1A">1a</A>
Present
address: Aventis Pharma Deutschland GmbH, 65926 Frankfurt, Germany
<A NAME="RS05503ST-1B">1b</A>
Present address: Provid Pharmaceuticals,
Piscataway, NJ 08854, USA
<A NAME="RS05503ST-2">2</A>
Pearson ND.
Prescott CD.
Chem. Biol.
1997,
4:
409
<A NAME="RS05503ST-3">3</A>
Baumann M.
Bischoff H.
Schmidt D.
Griesinger C.
J. Med. Chem.
2001,
44:
2172
<A NAME="RS05503ST-4">4</A>
Michael K.
Tor Y.
Chem.-Eur. J.
1998,
4:
2091
<A NAME="RS05503ST-5">5</A>
Stage TK.
Hertel KJ.
Uhlenbeck OC.
RNA
1995,
1:
95
<A NAME="RS05503ST-6">6</A>
Sears P.
Wong C.-H.
Angew. Chem. Int. Ed.
1999,
38:
2300
<A NAME="RS05503ST-7">7</A>
Hendrix M.
Priestley ES.
Joyce GF.
Wong C.-H.
J. Am. Chem.
Soc.
1997,
119:
3641
<A NAME="RS05503ST-8">8</A>
Tor Y.
Hermann T.
Westhof E.
Chem. Biol.
1985,
5:
277
<A NAME="RS05503ST-9">9</A>
Carter AP.
Clemons WM.
Brodersen DE.
Morgan-Warren RJ.
Wimberly BT.
Ramakrishnan V.
Nature
2000,
407:
340
<A NAME="RS05503ST-10">10</A>
Alper PB.
Hendrix M.
Sears P.
Wong CH.
J. Am. Chem. Soc.
1998,
120:
1965
<A NAME="RS05503ST-11">11</A>
Kavadias G.
Velkof S.
Belleau B.
Can.
J. Chem.
1978,
56:
404
<A NAME="RS05503ST-12A">12a</A>
Vasella A.
Witzig C.
Chiara JL.
Martin-Lomas M.
Helv.
Chim. Acta
1991,
74:
2073
<A NAME="RS05503ST-12B">12b</A>
Lemieux R.
Cushley S.
Can. J. Chem.
1963,
43:
858
<A NAME="RS05503ST-12C">12c</A>
Baeschlin DK.
Chaperon AR.
Green LG.
Hahn MG.
Ince SJ.
Ley SV.
Chem.-Eur.
J.
2000,
6:
172
<A NAME="RS05503ST-12D">12d</A>
Contour MO.
Deaye J.
Little M.
Wong E.
Carbohydr. Res.
1989,
193:
283
<A NAME="RS05503ST-13">13</A>
7: Rf = 0.81
(hexanes-EtOAc, 1:1); 1H NMR (300 MHz, CDCl3): δ = 7.40-7.28
(m, 10 H), 5.25 (d, J = 3.0
Hz, 1 H), 4.83 (dd, J = 10.1,
10.1 Hz, 2 H), 4.79 (dd, J = 10.2,
10.2 Hz, 2 H), 4.51 (d, J = 9.4
Hz, 1 H), 4.44 (dd, J = 6.3,
10.2 Hz, 1 H), 4.27 (dd, J = 6.8,
10.4 Hz, 1 H), 3.91 (dd, J = 6.6, 6.6 Hz, 1 H),
3.69 (dd, J = 3.0,
9.3 Hz, 1 H), 3.58 (dd, J = 9.4, 9.4
Hz, 1 H), 3.07 (s, 3 H), 3.03 (s, 3 H), 2.75 (m, 2 H), 1.32 (t, J = 7.4 Hz,
3 H); 13C NMR (75 MHz, CD3Cl): δ = 137.7, 137.0,
128.8, 128.6, 128.5, 128.4, 128.2, 85.9, 80.5, 76.1, 76.0, 74.1,
73.6, 67.1, 39.4, 37.8, 25.5, 15.5; HRMS (FAB+) Calcd
for m/z C24H32O9S3Na [(M + Na)+] 583.1106,
found 583.1112. 9: Rf = 0.38
(hexanes-EtOAc, 1:1); 1H NMR (300 MHz,
CDCl3): δ = 7.41 -7.30 (m,
10 H), 4.90 (dd, J = 11.1, 11.1
Hz, 2 H), 4.57 (dd, J = 11.1,11.1
Hz, 2 H), 4.32 (d, J = 9.5
Hz, 1 H), 3.74 (dd, J = 2.3,
4.5 Hz, 1 H), 3.78-3.65 (m, 2 H), 3.44 (dd, J = 4.7, 9.6
Hz, 1 H), 3.38 (dd, J = 6.7, 6.7
Hz, 1 H), 3.36 (m, 1 H), 2.82 (br s, 1 H), 2.75 (m, 2 H), 1.32 (t, J = 7.4 Hz,
3 H); 13C NMR (75 MHz, CD3Cl): δ = 138.2,
137.8, 128.8, 128.7, 128.4, 128.3, 128.1, 128.0, 84.7, 84.5, 78.0,
75.5, 73.9, 72.6, 70.7, 65.6, 24.9, 15.3; HRMS (FAB+)
Calcd for m/z C22H27N3O4SNa [(M + Na)+] 452.1619,
found 552.1624. 10: Rf = 0.53
(hexanes-Et2O, 1:2); 1H
NMR (300 MHz, CDCl3): δ = 7.40-7.32
(m, 10 H), 4.72 (dd, J = 11.6,
11.6 Hz, 2 H), 4.57 (s, 2 H), 4.24 (d, J = 10.3
Hz, 1 H), 4.08 (d, J = 3.2
Hz, 1 H), 3.77-3.67 (m, 2 H), 3.54 (dd, J
1 = 7.1,
7.1 Hz, 1 H), 3.40 (dd, J = 3.1,
9.4 Hz, 1 H), 2.75 (m, 2 H), 1.31 (t, J = 7.2
Hz, 3 H); 13C NMR (75 MHz, CD3Cl): δ =138.0,
137.2, 128.8, 128.7, 128.5, 128.3, 128.1, 128.0, 84.2, 81.3, 77.2,
73.9, 72.1, 69.4, 65.8, 62.1, 24.6, 15.2; HRMS (FAB+)
Calcd for m/z C22H27N3O4SNa [(M + Na)+] 452.1619,
found 552.1634.
<A NAME="RS05503ST-14">14</A>
Greenberg WA.
Priestley ES.
Sears PS.
Alper PB.
Rodenbohm C.
Hendrix M.
Hung S.-C.
Wong C.
J. Am. Chem. Soc.
1999,
121:
6527
<A NAME="RS05503ST-15">15</A>
Garegg PJ.
Adv.
Carbohydr. Chem. Biochem.
1997,
52:
179
<A NAME="RS05503ST-16">16</A>
Glycosylation.
General procedure. Thioethyl glycoside (0.1 mmol) and acceptor 2 (0.1 mmol) were coevaporated with toluene
and dried under vacuum. Et2O (1.5 mL), CH2Cl2 (0.5 mL),
toluene (0.2 mL), and 4 Å MS (40 mg) were added and the
mixture was cooled to -40 °C. Addition
of NIS (0.071 mmol) and AgOTf (0.020 mmol) followed. The mixture
was stirred for 5 h at -40 °C, EtOAc
(20 mL) was added and the filtrate was washed with Na2S2O3 (5% aqueous,
5 mL) and dried over MgSO4. After removal of the solvents,
the residue was purified by silica gel column chromatography to
afford the disaccharides as two diastereomers.
<A NAME="RS05503ST-17">17</A>
Deprotection.
General procedure. Protected di- or trisaccharide (0.052 mmol)
was dried 48 h at high vacuum, dissolved in MeOH (5 mL) and stirred
at room temperature with Pd(OH2)/C (60 mg) while
bubbling hydrogen through the mixture. After 5 h AcOH (2 mL, 50% aqueous)
was added to the solution and the mixture was hydrogenated for an
additional 2 h. The catalyst was filtered off and the solvent was
removed under reduced pressure. The residue was dissolved in water
(5 mL) and freeze dried to afford the deprotected aminoglycoside.
<A NAME="RS05503ST-18">18</A>
Hofstadler SA.
Griffey RH.
Chem. Rev.
2001,
101:
377